Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
WuXi AppTec’s stock price hit the daily max of 10% growth each day after its Shanghai IPO this month, vaulting its market cap to over $21 billion.
Nordic Pharma and Clinigen signed a deal to supply Trasylol, for reducing bleeding during surgery, to the Asia-Pacific region and South Africa.
PPD and its real-world data unit Evidera will be the first CRO to join MIT’s biotech think tank, starting with an evidence generation pilot project.
The strategic partnership tasks Evotec with applying its R&D toolkit to the discovery of solid tumor drugs that Celgene will then pick up and advance.
Icon has launched a paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA.
XenoGesis and BioAscent plan to integrate their drug discovery offerings.
PolarityTE, offering scant details, acquired an unnamed CRO to expand its R&D programs and appointed a new veterinary officer.
MD Anderson detailed the success of their collaboration with BMS, which connects academic researchers to simultaneous I-O studies in a leukemia pilot.
Startup financier Accelerator Life Science Partners formed two new advisory panels to guide its business decisions, while expanding into San Diego.
Pfizer expanded its work with XtalPi to develop an AI platform to model small-molecule drugs as part of its discovery and development efforts.